JP2018518481A - RORガンマ(RORγ)モジュレーター - Google Patents
RORガンマ(RORγ)モジュレーター Download PDFInfo
- Publication number
- JP2018518481A JP2018518481A JP2017563106A JP2017563106A JP2018518481A JP 2018518481 A JP2018518481 A JP 2018518481A JP 2017563106 A JP2017563106 A JP 2017563106A JP 2017563106 A JP2017563106 A JP 2017563106A JP 2018518481 A JP2018518481 A JP 2018518481A
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- acetamide
- cyclopropylmethanesulfonylphenyl
- alkyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HPLPYDNZBRTTQK-UHFFFAOYSA-N O=C(Cc(cc1)ccc1S(CC1CC1)(=O)=O)Nc1cc(Cl)c(-c(cccc2)c2OC(F)(F)F)c(Cl)c1 Chemical compound O=C(Cc(cc1)ccc1S(CC1CC1)(=O)=O)Nc1cc(Cl)c(-c(cccc2)c2OC(F)(F)F)c(Cl)c1 HPLPYDNZBRTTQK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
A1は、NR1又はCR1であり、R1はH又はメチルであり、メチルは、存在するならば、任意的に1以上のFで置換されていてもよい;
シクロプロピル部分は任意的に1以上のメチル及び1以上のFで置換されていてもよい;
A2〜A5はそれぞれ、N又はCR2〜CR5であり、ただしA2〜A5における4つの位置Aの2つ以下が同時にNであり得る;
R2〜R5は、独立にH、ハロゲン、アミノ、C(1〜3)アルコキシ、(ジ)C(1〜3)アルキルアミノ又はC(1〜6)アルキルである;
R6及びR7は、独立にH、F、メチル、エチル、ヒドロキシル又はメトキシであり、又はR2とR3が一緒になってカルボニルであり、全てのアルキル基は、存在するならば、任意的に1以上のFで置換されていてもよい;
R8は、H又はC(1〜6)アルキルである;
R9は、式II、III、IV及びVからなる群から選択される、
A10〜A13はそれぞれ、N又はCR10〜CR13であり、ただしA10〜A13における4つの位置Aの2つ以下が同時にNであり得る、
R10〜R13は、独立にH、ハロゲン、アミノ、C(1〜3)アルコキシ、(ジ)C(1〜3)アルキルアミノ又はC(1〜6)アルキルである、
X14は、C(6〜10)アリール又はC(1〜9)ヘテロアリールであり、全ての炭素原子は任意的にハロゲン、アミノ、シアノ、C(1〜3)アルコキシ、(ジ)C(1〜3)アルキルアミノ又はC(1〜3)アルキルで置換されていてもよい、
A20〜A27はそれぞれ、N又はCR20〜CR27であり、ただしA20〜A22における3つの位置Aの2つ以下が同時にNであり得、A23〜A27における5つの位置Aの3以下が同時にNであり得る、
R20〜R22は、独立にH、ハロゲン、アミノ、C(1〜3)アルコキシ、(ジ)C(1〜3)アルキルアミノ又はC(1〜6)アルキルである、
R23〜R27は、独立にH、ハロゲン、アミノ、シアノ、C(1〜3)アルコキシ、(ジ)C(1〜3)アルキルアミノ又はC(1〜3)アルキルである、
X28は、C(6〜10)アリール又はC(1〜9)ヘテロアリールであり、全ての炭素原子は任意的にハロゲン、アミノ、シアノ、C(1〜3)アルコキシ、(ジ)C(1〜3)アルキルアミノ又はC(1〜3)アルキルで置換されていてもよい、
A30は、N又はCであり、
A31は、O、カルボニル、NR31又はCR32であり、
R31は、H又はC(1〜6)アルキルであり、
R32は、H、OH又はC(1〜3)アルキルであり、全てのアルキル基は任意的に1以上のF又はOHで置換されていてもよい、
A33〜A42はそれぞれ、N又はCR33〜CR42であり、ただしA33〜A37における5つの位置Aの3つ以下が同時にNであり得、A38〜A42における5つの位置Aの3つ以下が同時にNであり得る、
R33〜R42は、独立にH、ハロゲン、アミノ、シアノ、C(1〜3)アルコキシ、(ジ)C(1〜3)アルキルアミノ又はC(1〜3)アルキルである。
本明細書に記載された化合物、例えば一般式A、B及びIの化合物が、下記の反応スキーム及び実施例又はそれらの変形にしたがって、容易に入手可能な出発物質、試薬及び慣用の合成手順を使用して、容易に調製され得る。反応の多くがまた、マイクロ波条件下で、又は慣用の加熱を使用して、又は他の技術、例えば固相試薬/スカベンジャー又はフローケミストリーを使用して行われ得る。これらの反応では、当業者に知られている(しかし、より詳細には言及されない)変形を使用することも可能である。例えば、特定の酸、塩基、試薬、カップリング剤、溶媒などが言及される場合には、他の適する酸、塩基、試薬、カップリング剤、溶媒などが使用され得、そして本発明の範囲に包含されることが理解される。さらに、本発明の化合物を調製する他の方法は、下記の反応スキーム及び実施例を考慮して、当業者に容易に明らかであろう。合成中間体及び最終生成物が潜在的に反応性の官能基、例えば所望の反応を妨害し得るアミノ、ヒドロキシル、チオール及びカルボン酸基を有する場合には、上記中間体の保護された形態を使用することが有利であり得る。保護基の選択、導入及びその後の除去の方法は、当業者に周知である。上記一般的反応順序を使用して得られた化合物は、不十分な純度のものであり得る。上記化合物は、有機化合物の精製法のいずれか、例えば結晶化又はシリカゲルもしくはアルミナカラムクロマトグラフィーを使用して、種々の溶媒を適する比率で使用して精製され得る。全てのあり得る立体異性体は、本発明の範囲内である。下記の記載において、可変のものは、特に断らない限り、上記で示された意味を有する。
r.t.:室温;HATU:2-(7-アザ-1H-ベンゾトリアゾール-1-イル)-1,1,3,3-テトラメチルウロニウムヘキサフルオロホスフェート;DMF:ジメチルホルムアミド;DiPEA:ジイソプロピルエチルアミン;DMAP:4-(ジメチルアミノ)ピリジン;DCC:N,N'-ジシクロヘキシルカルボジイミド;mCPBA:3-クロロペルオキシ安息香酸;TFA:トリフルオロ酢酸;TFAA:トリフルオロ酢酸無水物;THF:テトラヒドロフラン;DMSO:ジメチルスルホキシド;PTSA:p-トルエンスルホン酸;PyBOP:(ベンゾトリアゾール-1-イルオキシ)トリピロリジノホスホニウムヘキサフルオロホスフェート;EtOH:エタノール;TLC:薄層クロマトグラフィー;Ph3P:トリフェニルホスフィン;EDCI:1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド;BuLi:n-ブチルリチウム;PdCl2(dppf):[1,1'-ビス(ジフェニルホスフィノ)フェロセン]パラジウム(II)ジクロリド
実施例の阻害剤1〜47がRORγ GAL4レポーター遺伝子アッセイにおいて、RORγ活性を阻害する能力について試験された。アッセイ手順及び結果が以下に記載される。
Claims (15)
- 式Iに従う化合物又はその医薬的に許容される塩、
ここで、
A1は、NR1又はCR1であり、R1はH又はメチルであり、メチルは、存在するならば、任意的に1以上のFで置換されていてもよい;
シクロプロピル部分は任意的に1以上のメチル及び1以上のFで置換されていてもよい;
A2〜A5はそれぞれ、N又はCR2〜CR5であり、ただしA2〜A5における4つの位置Aの2つ以下が同時にNであり得る;
R2〜R5は、独立にH、ハロゲン、アミノ、C(1〜3)アルコキシ、(ジ)C(1〜3)アルキルアミノ又はC(1〜6)アルキルである;
R6及びR7は、独立にH、F、メチル、エチル、ヒドロキシル又はメトキシであり、又はR2とR3が一緒になってカルボニルであり、全てのアルキル基は、存在するならば、任意的に1以上のFで置換されていてもよい;
R8は、H又はC(1〜6)アルキルである;
R9は、式II、III、IV及びVからなる群から選択される、
式II中、
A10〜A13はそれぞれ、N又はCR10〜CR13であり、ただしA10〜A13における4つの位置Aの2つ以下が同時にNであり得る、
R10〜R13は、独立にH、ハロゲン、アミノ、C(1〜3)アルコキシ、(ジ)C(1〜3)アルキルアミノ又はC(1〜6)アルキルである、
X14は、C(6〜10)アリール又はC(1〜9)ヘテロアリールであり、全ての炭素原子は任意的にハロゲン、アミノ、シアノ、C(1〜3)アルコキシ、(ジ)C(1〜3)アルキルアミノ又はC(1〜3)アルキルで置換されていてもよい、
式III中、
A20〜A27はそれぞれ、N又はCR20〜CR27であり、ただしA20〜A22における3つの位置Aの2つ以下が同時にNであり得、A23〜A27における5つの位置Aの3以下が同時にNであり得る、
R20〜R22は、独立にH、ハロゲン、アミノ、C(1〜3)アルコキシ、(ジ)C(1〜3)アルキルアミノ又はC(1〜6)アルキルである、
R23〜R27は、独立にH、ハロゲン、アミノ、シアノ、C(1〜3)アルコキシ、(ジ)C(1〜3)アルキルアミノ又はC(1〜3)アルキルである、
X28は、C(6〜10)アリール又はC(1〜9)ヘテロアリールであり、全ての炭素原子は任意的にハロゲン、アミノ、シアノ、C(1〜3)アルコキシ、(ジ)C(1〜3)アルキルアミノ又はC(1〜3)アルキルで置換されていてもよい、
式IVおよびV中、
A30は、N又はCであり、
A31は、O、カルボニル、NR31又はCR32であり、
R31は、H又はC(1〜6)アルキルであり、
R32は、H、OH又はC(1〜3)アルキルであり、全てのアルキル基は任意的に1以上のF又はOHで置換されていてもよい、
A33〜A42はそれぞれ、N又はCR33〜CR42であり、ただしA33〜A37における5つの位置Aの3つ以下が同時にNであり得、A38〜A42における5つの位置Aの3つ以下が同時にNであり得る、
R33〜R42は、独立にH、ハロゲン、アミノ、シアノ、C(1〜3)アルコキシ、(ジ)C(1〜3)アルキルアミノ又はC(1〜3)アルキルである。 - A1がCR1である、請求項1に記載の化合物。
- A1がNR1である、請求項1に記載の化合物。
- R1が水素である、請求項1〜3のいずれか1項に記載の化合物。
- R6及びR7が両方ともHである、請求項1〜4のいずれか1項に記載の化合物。
- R8がHである、請求項1〜5のいずれか1項に記載の化合物。
- A2〜A5における全ての位置AがCR2〜R5であり、R2〜R5における全ての位置RがHである、請求項1〜6のいずれか1項に記載の化合物。.
- R9が式IIに従う、請求項1〜7のいずれか1項に記載の化合物、ここで、
A10〜A13はそれぞれ、N又はCR10〜CR13であり、ただしA10〜A13における4つの位置Aの2つ以下が同時にNであり得、
R10〜R13は独立にH、アミノ、ハロゲン、C(1〜3)アルコキシ、(ジ)C(1〜3)アルキルアミノ又はC(1〜6)アルキルであり、
X14はC(6)アリール又はC(1〜5)ヘテロアリールであり、全ての炭素原子は任意的にハロゲン、シアノ、C(1〜3)アルコキシ、(ジ)C(1〜3)アルキルアミノ又はC(1〜3)アルキルで置換されていてもよい。 - R9が式IIIに従う、請求項1〜7のいずれか1項に記載の化合物、ここで、
A20〜A27はそれぞれ、N又はCR20〜CR27であり、ただしA20〜A22における3つの位置Aの2つ以下が同時にNであり得、A23〜A27における5つの位置Aの3つ以下が同時にNであり得る、
R20〜R22は、独立にH、ハロゲン、アミノ、C(1〜3)アルコキシ、(ジ)C(1〜3)アルキルアミノ又はC(1〜6)アルキルである、
R23〜R27は、独立にH、ハロゲン、シアノ、アミノ、C(1〜3)アルコキシ、(ジ)C(1〜3)アルキルアミノ又はC(1〜3)アルキルである、
X28は、C(6)アリール又はC(1〜5)ヘテロアリールであり、全ての炭素原子は任意的にハロゲン、シアノ、C(1〜3)アルコキシ、(ジ)C(1〜3)アルキルアミノ又はC(1〜3)アルキルで置換されていてもよい。 - R9が式IV又はVに従う、請求項1〜7のいずれか1項に記載の化合物、ここで、
A30は、N又はCである、
A31は、O、カルボニル、NR31又はCR32である、
R31は、H又はC(1〜6)アルキルである、
R32は、H、OH又はC(1〜6)アルキルであり、全てのアルキル基は任意的に1以上のF又はOHで置換されていてもよい、
A33〜A42はそれぞれ、N又はCR33〜CR42であり、ただし5つの位置A33〜A37の3つ以下が同時にNであり得、5つの位置A38〜A42の3つ以下が同時にNであり得る、
R33〜R42は、独立にH、ハロゲン、シアノ、C(1〜3)アルコキシ、(ジ)C(1〜3)アルキルアミノ又はC(1〜3)アルキルである。 - 下記群から選択される、請求項1に記載の化合物、
2-(4-シクロプロピルメタンスルホニルフェニル)-N-(3-フェノキシ-4-フェニルフェニル)アセトアミド;
2-(4-シクロプロピルメタンスルホニルフェニル)-N-[4-(3-フルオロフェニル)-3-(3-メトキシフェノキシ)フェニル]アセトアミド.;
2-(4-シクロプロピルメタンスルホニルフェニル)-N-[3-(3-メトキシフェノキシ)-4-(4-メチル-1H-イミダゾール-1-イル)フェニル]アセトアミド;
N-[3-(3-クロロフェノキシ)-4-(3-フルオロフェニル)フェニル]-2-(4-シクロプロピルメタンスルホニルフェニル)アセトアミド;
N-[3-(3-クロロフェノキシ)-4-(3,4-ジフルオロフェニル)フェニル]-2-(4-シクロプロピルメタンスルホニルフェニル)アセトアミド;
N-[3-(3-シアノフェノキシ)-4-(3,4-ジフルオロフェニル)フェニル]-2-(4-シクロプロピルメタンスルホニルフェニル)アセトアミド;
2-(4-シクロプロピルメタンスルホニルフェニル)-N-[3-(3-メトキシフェノキシ)-4-(5-メチル-1H-ピラゾール-1-イル)フェニル]アセトアミド;
N-[3-(3-クロロフェノキシ)-4-(3,5-ジフルオロフェニル)フェニル]-2-(4-シクロプロピルメタンスルホニルフェニル)アセトアミド;
N-[4-(4-シアノフェニル)-3-(3-フルオロフェノキシ)フェニル]-2-(4-シクロプロピルメタンスルホニルフェニル)アセトアミド;
N-[3-(3-クロロフェノキシ)-4-(3-シアノフェニル)フェニル]-2-(4-シクロプロピルメタンスルホニルフェニル)アセトアミド;
2-(4-シクロプロピルメタンスルホニルフェニル)-N-[4-(3-フルオロフェニル)-3-[3-(トリフルオロメチル)フェノキシ]フェニル]アセトアミド;
2-(4-シクロプロピルメタンスルホニルフェニル)-N-[3-(3-フルオロフェノキシ)-4-(4-フルオロフェニル)フェニル]アセトアミド;
2-(4-シクロプロピルメタンスルホニルフェニル)-N-[3-(3,5-ジフルオロフェノキシ)-4-(3-フルオロフェニル)フェニル]アセトアミド;
2-[4-(シクロプロピルスルファモイル)フェニル]-N-[3-(3-メトキシフェノキシ)-4-(4-メチル-1H-イミダゾール-1-イル)フェニル]アセトアミド;
2-[4-(シクロプロピルスルファモイル)フェニル]-N-[3-(3-メトキシフェノキシ)-4-(5-メチル-1H-ピラゾール-1-イル)フェニル]アセトアミド;
2-[4-(シクロプロピルスルファモイル)フェニル]-N-[4-(3-フルオロフェニル)-3-(3-メトキシフェノキシ)フェニル]アセトアミド;
N-[3-(3-クロロフェノキシ)-4-(3-フルオロフェニル)フェニル]-2-[4-(シクロプロピルスルファモイル)フェニル]アセトアミド;
N-[3-(3-クロロフェノキシ)-4-(3,4-ジフルオロフェニル)フェニル]-2-[4-(シクロプロピルスルファモイル)フェニル]アセトアミド;
2-[4-(シクロプロピルスルファモイル)フェニル]-N-[4-(3-フルオロフェニル)-3-[3-(トリフルオロメチル)フェノキシ]フェニル]アセトアミド;
2-(4-シクロプロピルメタンスルホニルフェニル)-N-(5-フェノキシ-4-フェニル-1,3-チアゾール-2-イル)アセトアミド;
2-(4-シクロプロピルメタンスルホニルフェニル)-N-[4-フェニル-5-(ピリジン-3-イルオキシ)-1,3-チアゾール-2-イル]アセトアミド;
N-(5-ベンゾイル-4-フェニル-1,3-チアゾール-2-イル)-2-(4-シクロプロピルメタンスルホニルフェニル)アセトアミド;
N-[5-(4-クロロベンゾイル)-4-(3-クロロフェニル)-1,3-チアゾール-2-イル]-2-(4-シクロプロピルメタンスルホニルフェニル)アセトアミド;
2-(4-シクロプロピルメタンスルホニルフェニル)-N-(4-フェニルチオフェン-2-イル)アセトアミド;
2-(4-シクロプロピルメタンスルホニルフェニル)-N-[4-(ピリジン-3-イル)チオフェン-2-イル]アセトアミド;
N-(5-ベンゾイル-4-フェニル-1,3-チアゾール-2-イル)-2-[4-(シクロプロピルスルファモイル)フェニル]アセトアミド;
N-(5-ベンゾイル-4-フェニルチオフェン-2-イル)-2-(4-シクロプロピルメタンスルホニルフェニル)アセトアミド;
N-{3-クロロ-4-[2-(トリフルオロメトキシ)フェニル]フェニル}-2-(4-シクロプロピルメタンスルホニルフェニル)アセトアミド;
2-(4-シクロプロピルメタンスルホニルフェニル)-N-{3-メチル-4-[2-(トリフルオロメトキシ)フェニル]フェニル}アセトアミド;
2-(4-シクロプロピルメタンスルホニルフェニル)-N-{3,5-ジクロロ-4-[2-(トリフルオロメトキシ)フェニル]フェニル}アセトアミド;
2-(4-シクロプロピルメタンスルホニルフェニル)-N-{4-メチル-5-[2-(トリフルオロメトキシ)フェニル]ピリジン-2-イル}アセトアミド;
2-(4-シクロプロピルメタンスルホニルフェニル)-N-{6-メチル-5-[2-(トリフルオロメトキシ)フェニル]ピリジン-2-イル}アセトアミド;
N-{3-クロロ-4-[2-(トリフルオロメトキシ)フェニル]フェニル}-2-[4-(シクロプロピルスルファモイル)フェニル]アセトアミド;
2-[4-(シクロプロピルスルファモイル)フェニル]-N-{6-メチル-5-[2-(トリフルオロメトキシ)フェニル]ピリジン-2-イル}アセトアミド;
2-[4-(シクロプロピルスルファモイル)フェニル]-N-{4-メチル-5-[2-(トリフルオロメトキシ)フェニル]ピリジン-2-イル}アセトアミド;
2-[4-(シクロプロピルスルファモイル)フェニル]-N-{3-メチル-4-[2-(トリフルオロメトキシ)フェニル]フェニル}アセトアミド;
2-(4-シクロプロピルメタンスルホニルフェニル)-N-{4,6-ジメチル-5-[2-(トリフルオロメトキシ)フェニル]ピリジン-2-イル}アセトアミド;
2-(4-シクロプロピルメタンスルホニルフェニル)-N-[4-(4-メチル-1H-イミダゾール-1-イル)フェニル]アセトアミド;
2-(4-シクロプロピルメタンスルホニルフェニル)-N-[4-(5-メチル-1H-イミダゾール-1-イル)フェニル]アセトアミド;
2-(4-シクロプロピルメタンスルホニルフェニル)-N-[4-(3-メチル-1H-ピラゾール-1-イル)フェニル]アセトアミド;
2-(4-シクロプロピルメタンスルホニルフェニル)-N-[4-(5-メチル-1H-ピラゾール-1-イル)フェニル]アセトアミド;
2-(4-シクロプロピルメタンスルホニルフェニル)-N-[4-(4-メチル-1H-ピラゾール-1-イル)フェニル]アセトアミド;
2-(4-シクロプロピルメタンスルホニルフェニル)-N-[4-(1,3-オキサゾール-5-イル)フェニル]アセトアミド;
2-(4-シクロプロピルメタンスルホニルフェニル)-N-[4-(1H-ピラゾール-1-イル)フェニル]アセトアミド;
2-(4-シクロプロピルメタンスルホニルフェニル)-N-[4-(1H-イミダゾール-1-イル)フェニル]アセトアミド;
2-(4-シクロプロピルメタンスルホニルフェニル)-N-[4-(1H-1,2,4-トリアゾール-1-イル)フェニル]アセトアミド;及び
2-(4-シクロプロピルメタンスルホニルフェニル)-N-[4-(1,2,4-オキサジアゾール-3-イル)フェニル]アセトアミド。 - 治療での使用のための、請求項1〜11のいずれか1項に記載の化合物又はその医薬的に許容される塩。
- RORγ媒介性の疾病又は症状の処置のための、請求項1〜11のいずれか1項に記載の化合物又はその医薬的に許容される塩。
- 請求項1〜11のいずれか1項に記載の式Iの化合物又はその医薬的に許容される塩と1以上の医薬的に許容される賦形剤とを含む医薬組成物。
- 少なくとも1つの追加の治療的に活性な剤をさらに含む、請求項14に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15170764.3A EP3101008A1 (en) | 2015-06-05 | 2015-06-05 | Ror gamma (rory) modulators |
EP15170764.3 | 2015-06-05 | ||
PCT/EP2016/062712 WO2016193470A1 (en) | 2015-06-05 | 2016-06-03 | Ror gamma (rory) modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018518481A true JP2018518481A (ja) | 2018-07-12 |
JP6843076B2 JP6843076B2 (ja) | 2021-03-17 |
Family
ID=53284142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017563106A Active JP6843076B2 (ja) | 2015-06-05 | 2016-06-03 | RORガンマ(RORγ)モジュレーター |
Country Status (15)
Country | Link |
---|---|
US (1) | US10259782B2 (ja) |
EP (2) | EP3101008A1 (ja) |
JP (1) | JP6843076B2 (ja) |
KR (1) | KR20180040558A (ja) |
CN (1) | CN108430973B (ja) |
AU (1) | AU2016272018B2 (ja) |
BR (1) | BR112017026224A2 (ja) |
CA (1) | CA2988008A1 (ja) |
ES (1) | ES2794751T3 (ja) |
IL (1) | IL256037B (ja) |
MX (1) | MX2017015739A (ja) |
PL (1) | PL3303292T3 (ja) |
PT (1) | PT3303292T (ja) |
RU (1) | RU2727191C2 (ja) |
WO (1) | WO2016193470A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3101009A1 (en) | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Ror gamma (rory) modulators |
AU2016374294B2 (en) | 2015-12-15 | 2019-06-27 | Astrazeneca Ab | Isoindole compounds |
TW201815388A (zh) | 2016-07-14 | 2018-05-01 | 印度商卡迪拉保健有限公司 | 作為RORγ調節劑之新穎化合物 |
JP2019520400A (ja) | 2016-07-14 | 2019-07-18 | カディラ ヘルスケア リミティド | 新規シクロプロピル誘導体 |
US10196350B2 (en) | 2016-12-05 | 2019-02-05 | Lead Pharma Holding B.V. | ROR gamma (RORγ) modulators |
US10844017B2 (en) | 2017-02-09 | 2020-11-24 | Fudan University | Biaryl compound, preparation method and use thereof |
EP3638661A1 (en) | 2017-06-14 | 2020-04-22 | Astrazeneca AB | 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators |
WO2021228215A1 (zh) * | 2020-05-15 | 2021-11-18 | 上海辉启生物医药科技有限公司 | 可用作RORγ调节剂的联芳基类化合物 |
CN111658651B (zh) * | 2020-06-08 | 2021-08-03 | 重庆医科大学附属第一医院 | CQMU151在制备治疗Th17细胞介导自身免疫病药物中的应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012100734A1 (en) * | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Compounds useful as retinoid-related orphan receptor gamma modulators |
WO2013029338A1 (en) * | 2011-09-01 | 2013-03-07 | Glaxo Group Limited | Novel compounds |
WO2013171729A2 (en) * | 2013-01-08 | 2013-11-21 | Glenmark Pharmaceuticals S.A. | Aryl and heteroaryl amide compounds as rorgamat modulator |
WO2013178362A1 (en) * | 2012-05-31 | 2013-12-05 | Phenex Pharmaceuticals Ag | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma] |
WO2014125426A1 (en) * | 2013-02-15 | 2014-08-21 | Aurigene Discovery Technologies Limited | Trisubstituted heterocyclic derivatives as ror gamma modulators |
WO2014179564A1 (en) * | 2013-05-01 | 2014-11-06 | Vitae Pharmaceuticals, Inc. | Thiazalopyrrolidine inhibitors of ror-gamma |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6461960B2 (ja) | 2013-12-05 | 2019-01-30 | リード ファーマ ホールディング ビー.ブイ. | RORガンマ(γ)モジュレータ |
-
2015
- 2015-06-05 EP EP15170764.3A patent/EP3101008A1/en not_active Withdrawn
-
2016
- 2016-06-03 AU AU2016272018A patent/AU2016272018B2/en not_active Ceased
- 2016-06-03 EP EP16730288.4A patent/EP3303292B1/en active Active
- 2016-06-03 PT PT167302884T patent/PT3303292T/pt unknown
- 2016-06-03 ES ES16730288T patent/ES2794751T3/es active Active
- 2016-06-03 US US15/579,143 patent/US10259782B2/en not_active Expired - Fee Related
- 2016-06-03 WO PCT/EP2016/062712 patent/WO2016193470A1/en active Application Filing
- 2016-06-03 JP JP2017563106A patent/JP6843076B2/ja active Active
- 2016-06-03 CN CN201680043515.7A patent/CN108430973B/zh active Active
- 2016-06-03 MX MX2017015739A patent/MX2017015739A/es unknown
- 2016-06-03 KR KR1020187000280A patent/KR20180040558A/ko not_active Application Discontinuation
- 2016-06-03 BR BR112017026224-0A patent/BR112017026224A2/pt not_active IP Right Cessation
- 2016-06-03 RU RU2017145929A patent/RU2727191C2/ru active
- 2016-06-03 CA CA2988008A patent/CA2988008A1/en not_active Abandoned
- 2016-06-03 PL PL16730288T patent/PL3303292T3/pl unknown
-
2017
- 2017-11-30 IL IL256037A patent/IL256037B/en active IP Right Grant
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012100734A1 (en) * | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Compounds useful as retinoid-related orphan receptor gamma modulators |
WO2013029338A1 (en) * | 2011-09-01 | 2013-03-07 | Glaxo Group Limited | Novel compounds |
WO2013178362A1 (en) * | 2012-05-31 | 2013-12-05 | Phenex Pharmaceuticals Ag | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma] |
WO2013171729A2 (en) * | 2013-01-08 | 2013-11-21 | Glenmark Pharmaceuticals S.A. | Aryl and heteroaryl amide compounds as rorgamat modulator |
WO2014125426A1 (en) * | 2013-02-15 | 2014-08-21 | Aurigene Discovery Technologies Limited | Trisubstituted heterocyclic derivatives as ror gamma modulators |
WO2014179564A1 (en) * | 2013-05-01 | 2014-11-06 | Vitae Pharmaceuticals, Inc. | Thiazalopyrrolidine inhibitors of ror-gamma |
Non-Patent Citations (2)
Title |
---|
ACS MEDICINAL CHEMISTRY LETTERS, vol. Vol.6(7), JPN6020010644, 2015, pages 787 - 792, ISSN: 0004236218 * |
BIOORGANIC & MEDICINAL CHEMISTRY, vol. Vol.22(2), JPN6020010645, 2014, pages 692 - 702, ISSN: 0004236219 * |
Also Published As
Publication number | Publication date |
---|---|
EP3101008A1 (en) | 2016-12-07 |
EP3303292A1 (en) | 2018-04-11 |
WO2016193470A1 (en) | 2016-12-08 |
PT3303292T (pt) | 2020-05-27 |
AU2016272018B2 (en) | 2020-08-27 |
MX2017015739A (es) | 2018-05-02 |
PL3303292T3 (pl) | 2020-09-07 |
CA2988008A1 (en) | 2016-12-08 |
ES2794751T3 (es) | 2020-11-19 |
KR20180040558A (ko) | 2018-04-20 |
BR112017026224A2 (pt) | 2018-09-11 |
CN108430973B (zh) | 2021-09-21 |
CN108430973A (zh) | 2018-08-21 |
US10259782B2 (en) | 2019-04-16 |
AU2016272018A1 (en) | 2018-01-04 |
RU2017145929A3 (ja) | 2019-12-04 |
EP3303292B1 (en) | 2020-03-18 |
US20180170863A1 (en) | 2018-06-21 |
IL256037B (en) | 2021-02-28 |
JP6843076B2 (ja) | 2021-03-17 |
IL256037A (en) | 2018-01-31 |
RU2017145929A (ru) | 2019-07-10 |
RU2727191C2 (ru) | 2020-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6843076B2 (ja) | RORガンマ(RORγ)モジュレーター | |
JP6754779B2 (ja) | RORガンマ(RORγ)モジュレーター | |
JP6754778B2 (ja) | RORガンマ(RORγ)モジュレーター | |
EP3101005A1 (en) | Ror gamma (rory) modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190529 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200312 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200327 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200624 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200826 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210127 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210222 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6843076 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |